B+
Bull case
25%
Probability
Target price
$26.00
Analysis reference price unavailable
Analysis 2026-09-24 · RankAlpha Sentiment Codex
CBIO
Crescent BiopharmaCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$15.00
Analysis reference price unavailable
Analysis 2026-09-24 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$7.00
Analysis reference price unavailable
Analysis 2026-09-24 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-24
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+79.2
Score
AI commentary
The company-confirmed pipeline timetable and extended runway improve milestone visibility, but the deterministic prior remains directionally neutral and decisive clinical data are pending. The packet does not establish a reliable recent price reaction, analyst revision trend, or sufficient social and options coverage; the zero-valued sentiment fields above denote unavailable measurements, not neutral observations. The September third-party article is not treated as company confirmation.
RankAlpha Sentiment Codex - 2026-09-24
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-12-31catalystCR-002 global trial initiationHigh impact
Crescent said its global Phase 1/2 trial of the PD-L1-targeted ADC CR-002 was on track to begin in the second half of 2026. The earlier mid-2026 IND target is not confirmed as completed in the supplied evidence; trial initiation is the milestone to verify. [#8-K-2026-07-30] [#SEC-8K-2026-07-30] SEC earnings exhibit.
2027-03-31eventInitial ASCEND proof-of-concept dataHigh impact
Crescent expects first-quarter 2027 CR-001 data covering safety, pharmacology and preliminary antitumor activity across solid-tumor cohorts. Clinical interpretation, rather than enrollment progress alone, is the principal near-term valuation test. [#SEC-8K-2026-07-30] SEC earnings exhibit.
2027-03-31eventCR-003 initial clinical dataHigh impact
Kelun-Biotech's China Phase 1/2 trial of the ITGB6-targeted ADC CR-003 is ongoing, with proof-of-concept data expected in the first quarter of 2027. The readout offers a distinct pipeline test but remains early-stage and partner-executed. [#SEC-8K-2026-07-30] SEC earnings exhibit.
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-24 • Updated nightlySource: Internal modelMethodology